PHIO - Phio Pharmaceuticals Corp.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
5.43M
Enterprise Value 3
-4.37M
Trailing P/E
N/A
Forward P/E 1
-0.61
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
69.56
Price/Book (mrq)
0.55
Enterprise Value/Revenue 3
-56.03
Enterprise Value/EBITDA 6
0.59

Trading Information

Stock Price History

Beta (3Y Monthly) 1.83
52-Week Change 3-45.41%
S&P500 52-Week Change 38.78%
52 Week High 30.5250
52 Week Low 30.1900
50-Day Moving Average 30.2788
200-Day Moving Average 30.3795

Share Statistics

Avg Vol (3 month) 3150.72k
Avg Vol (10 day) 3212.21k
Shares Outstanding 525.59M
Float 25.07M
% Held by Insiders 15.93%
% Held by Institutions 113.76%
Shares Short (Sep 30, 2019) 4173.49k
Short Ratio (Sep 30, 2019) 41.15
Short % of Float (Sep 30, 2019) 40.70%
Short % of Shares Outstanding (Sep 30, 2019) 40.68%
Shares Short (prior month Aug 30, 2019) 4248.34k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Jan 8, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-9,526.92%

Management Effectiveness

Return on Assets (ttm)-51.21%
Return on Equity (ttm)-113.63%

Income Statement

Revenue (ttm)78k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-4.19M
EBITDA -7.36M
Net Income Avi to Common (ttm)-7.37M
Diluted EPS (ttm)-0.4450
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)10.82M
Total Cash Per Share (mrq)0.42
Total Debt (mrq)567k
Total Debt/Equity (mrq)5.84
Current Ratio (mrq)5.87
Book Value Per Share (mrq)0.39

Cash Flow Statement

Operating Cash Flow (ttm)-7.86M
Levered Free Cash Flow (ttm)-5.14M